FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to								
Section 16. Form 4 or Form 5								
obligations may continue. See								
Instruction 1(b).								

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Abrams Michael J.						Arbutus Biopharma Corp [ TKMR ]								eck all appl Direc			son(s) to Iss 10% Ow Other (s	vner
(Last) (First) (Middle) C/O ARBUTUS BIOPHARMA CORP. SUITE 100, 8900 GLENLYON PARKWAY							3. Date of Earliest Transaction (Month/Day/Year) 09/11/2015								below) below) Managing Director			
(Street) BURNABY A1 V5J 5J8  (City) (State) (Zip)					_   4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								e) <mark>X</mark> Form	or Joint/Group Filing (Check Applicable orm filed by One Reporting Person orm filed by More than One Reporting erson			
		Tab	le I - N	on-Deri	ivativ	e Sec	curit	ties Ac	quired	, Di	sposed o	of, or Be	neficial	ly Owne				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/)					ction	2A. Exe ) if ar	Deemed cution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a		(A) or	5. Amo Securit Benefic Owned	unt of ies ially Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) or (D)	Price	Report Transa (Instr. 3	ed ction(s) and 4)			
Common Shares 09/11/20							15		М		17,044	A	\$0.4444	(1) 2	7,919		D	
		7	Table II								posed of, convertil			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (right to	\$0.4444 <sup>(1)</sup>	09/11/2015			М			17,044	03/30/20	008	09/12/2015	Common shares	17,044	\$0.0	0		D	

## **Explanation of Responses:**

1. Expressed in Canadian dollars.

## Remarks:

/s/ Michael J. Abrams

09/15/2015

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.